SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings (ONDS) is gaining traction following multiple analyst upgrades and an increased revenue outlook, with community discussions centered on its potential in drone and autonomous systems for critical infrastructure and defense. Investors are actively debating the stock's volatility, weighing recent upgrades and anticipated large contracts against observed market dynamics and short-term trading patterns.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant pre-earnings rally, driven by growing optimism for its advanced AI hardware and strategic importance as a domestic chip manufacturer. The community is vigorously debating a potential short squeeze, with many anticipating substantial upside on upcoming foundry and product announcements, while some caution about a post-earnings pullback.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is a hot topic amidst widespread speculation surrounding a highly anticipated deal that could significantly expand its cloud and data operations. While many investors are optimistic about substantial future gains, citing its AI infrastructure growth and a notable $400 price target from a major firm, others express caution regarding its debt levels and recent price volatility, with the community actively debating its short-term direction.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing a significant surge after President Trump announced a "framework deal" with NATO regarding Greenland and paused planned European tariffs, prompting a relief rally. The community is sharply divided, with bulls celebrating immediate gains from this "TACO Trade," while skeptics widely debate if the bounce is a genuine market shift or a politically orchestrated "fake pump" ahead of broader underlying market concerns.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as recent token burns aim to boost scarcity, alongside its evolving role as a 'universal gas token' and the introduction of new Web3 games and 'Learn & Earn' features. The community remains divided, with some highlighting its long-term move-to-earn potential and ecosystem growth, while others caution about its volatility.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst strong community discussion surrounding its strategic push into artificial intelligence, particularly the anticipated spin-off and listing of its T-Head AI chip unit and the growing integration of its Qwen AI models across its ecosystem. This focus is fueling bullish sentiment and talk of a re-rating for Chinese tech, even as some market participants express caution regarding broader macroeconomic factors and geopolitical dynamics.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed Inc. is trending after its subsidiary, Lucid Diagnostics, secured a significant U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, expanding access across a large healthcare system. The community is buzzing about the stock's low float and high short interest, with many anticipating a substantial short squeeze and extreme volatility. Discussions are active regarding potential continued upward momentum versus concerns about profit-taking and possible dilution.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its soquelitinib drug, showcasing excellent safety and promising efficacy in atopic dermatitis. This has ignited a passionate debate, with bulls celebrating the potential of a "disease-modifying" breakthrough and anticipating a short squeeze due to perceived institutional interest. Conversely, bears are warning of significant overvaluation for a clinical-stage company and predicting a substantial pullback due to an impending public offering, which many view as dilution.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is experiencing a notable surge after President Trump announced a "framework deal" with NATO on Greenland, leading to the cancellation of planned tariffs on Europe. This "TACO" trade has sparked widespread community discussion, with bulls celebrating the predictable bounce while others express frustration over the market's politically-driven swings. The abrupt reversal of tariff threats has significantly eased geopolitical concerns, benefiting the tech-heavy index.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is trending due to significant community discussion surrounding the potential passage of the 'Clarity Act,' which many believe will bring increased liquidity and regulatory clarity to the crypto market. Ongoing developments related to Do Kwon's sentencing and Kraken's reversal on delisting LUNC are also fueling intense engagement, with many anticipating a major resurgence for the token fueled by ecosystem projects and burning mechanisms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat...

The End of Shots? 5 Biotech Stocks Rethinking Diabetes

The End of Shots? 5 Biotech Stocks Rethinking Diabetes The End of Shots? 5 Biotech Stocks Rethinking Diabetes PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Avant Technologies Inc...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Average Rating of "Hold" from Analysts

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given a consensus rating of "Hold" by the five brokerages that are covering the stock, MarketBeat Ratings reports. One...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been assigned a consensus rating of "Hold" from the five research firms that are currently covering the firm, MarketBeat...

Guggenheim Cuts Eledon Pharmaceuticals (NASDAQ:ELDN) Price Target to $8.00

Guggenheim decreased their price objective on shares of Eledon Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday...

Eledon Pharmaceuticals (NASDAQ:ELDN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01...

Best Momentum Stocks to Buy for July 14th

ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.

New Strong Buy Stocks for July 14th

WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Eledon Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.20	--	--	N/A
Q3 '25	-$0.25	-$0.21	16.56%	BEAT
Q2 '25	-$0.23	-$0.13	43.48%	BEAT
Q1 '25	-$0.26	-$0.08	69.62%	BEAT
Q4 '24	-$0.31	-$0.64	-105.35%	MISSED

ELDN
Eledon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ELDN News

ELDNEledon Pharmaceuticals Inc